Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited
Key Takeaways
- Novo Nordisk allows Wegovy at room temperature below 86 degrees Fahrenheit for up to 28 days
- The window is half of Ozempic's 56 days, even though both contain semaglutide, because of different pen formats and stability data
- Each Wegovy pen is single-dose; the 28-day window applies before use, with no separate in-use window
- The titration ladder (0.25, 0.5, 1.0, 1.7, 2.4 mg) means patients receive different pen strengths over 16 to 20 weeks
- Cumulative room-temperature tracking matters most for stockpiled pens that have not yet reached use
Direct answer
A Wegovy pen can stay at room temperature below 86 degrees Fahrenheit for up to 28 days, per Novo Nordisk labeling. This applies whether opened or unopened, single-dose or unused. Each pen is single-dose, so the 28-day window measures the time from manufacture or last refrigeration to injection. Freezing is a discard condition. The Wegovy 28-day window is shorter than Ozempic's 56-day window despite both medications containing semaglutide.
Get medications from a trusted source
FormBlends sources through 503A compounding pharmacies with third-party purity testing on every batch.
Start Free Assessment →Table of contents
- The Wegovy storage spec from Novo Nordisk
- Why Wegovy and Ozempic have different storage windows
- The single-dose pen format and what it changes
- The five Wegovy dose strengths and titration ladder
- How heat affects Wegovy
- Freezing and the do-not-use rule
- Stockpile management across dose changes
- What changes for compounded semaglutide at weight-loss doses
- The contrary view: margin in the 28-day spec
- Decision framework for warm Wegovy pens
- FAQ
- Sources
The Wegovy storage spec from Novo Nordisk
Wegovy prescribing information from Novo Nordisk specifies:
- Refrigerated storage: 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) until use
- Room-temperature allowance: below 30 degrees Celsius (86 degrees Fahrenheit), up to 28 days
- Do not freeze; discard pens that have been frozen
- Protect from light by keeping in the original carton
The 28-day window is the manufacturer's commitment for Wegovy specifically. It is shorter than Ozempic's 56-day window and longer than Zepbound's 21-day window. The numbers reflect each product's specific stability testing.
Wegovy is the only FDA-approved injectable GLP-1 medication specifically indicated for chronic weight management at the time of this article's publication, alongside Zepbound. Ozempic is approved for type 2 diabetes, with off-label prescribing for weight loss. The dosing schedules differ because the weight-management approval requires higher doses than the diabetes approval.
Why Wegovy and Ozempic have different storage windows
Both Wegovy and Ozempic are semaglutide. Both are manufactured by Novo Nordisk. Yet Wegovy carries a 28-day room-temperature allowance and Ozempic carries 56 days.
The reasons are not about the active ingredient. Semaglutide is the same molecule in both products. The differences come from:
- Pen format: Wegovy is single-dose; Ozempic is multi-dose
- Concentration: Wegovy comes in five strengths (0.25, 0.5, 1.0, 1.7, 2.4 mg); Ozempic comes in three (0.25/0.5 mg, 1 mg, 2 mg multi-dose)
- Excipient formulation: subtle differences in buffer, preservative, and stabilizer composition
- Stability data submitted for each product: Novo Nordisk tested each product separately
- Indication-specific factors: weight management requires higher cumulative doses, which affects the formulation and pen design
The label numbers reflect what each product's stability testing supports. Wegovy's data supports 28 days; Ozempic's data supports 56 days. The difference is not a statement that Wegovy is less stable. It is a statement about what Novo Nordisk tested and committed to.
Patients using both medications at different times (uncommon but possible) cannot apply Ozempic's rules to Wegovy or vice versa. Each follows its own label.
The single-dose pen format and what it changes
Wegovy is dispensed as single-dose, prefilled pens. Each pen delivers one weekly dose at a fixed strength and is discarded after use.
Implications:
No in-use window. Multi-dose pens like Ozempic have a 56-day window starting at first injection. Wegovy has no equivalent because each pen is used once. The 28-day room-temperature window applies before use.
Per-pen tracking. Each pen has its own clock. A patient with four pens received in May has four separate 28-day windows that all started at receipt (or earlier, depending on when the pens left manufacturing).
No partial-pen waste at expiration. Multi-dose Ozempic pens sometimes reach 56 days with doses remaining; those doses are discarded with the pen. Wegovy avoids this specific waste because each pen is one dose by design.
Different waste pattern at dose changes. Wegovy's dose-ladder titration means patients regularly move from one strength to the next. Pens at the previous strength may be discarded with no use if the dose change is scheduled before all pens at that strength are used.
The single-dose format simplifies some aspects of storage and complicates others. The 28-day room-temperature window matters more per pen because there is no in-use period to absorb it.
The five Wegovy dose strengths and titration ladder
Wegovy is titrated up from a starting dose to a maintenance dose over 16 to 20 weeks. The five doses, in order:
- 0.25 mg weekly for 4 weeks
- 0.5 mg weekly for 4 weeks
- 1.0 mg weekly for 4 weeks
- 1.7 mg weekly for 4 weeks
- 2.4 mg weekly as maintenance dose
Patients receive pens at the current strength. When titrating up, they receive new pens at the next strength and stop using the previous strength. This is why pen storage planning during titration is more complicated than during maintenance.
Storage implications during titration:
- A typical titration period uses four pens per strength
- If the patient does not finish all four pens by the titration date, remaining pens at the lower strength are discarded
- Insurance and pharmacy refill timing usually align with titration dates, minimizing waste
- Stockpiling pens beyond the current titration step is uncommon and not generally recommended
For patients who pause therapy and resume at a later titration step (under prescriber guidance), pens of the lower strength may sit refrigerated for extended periods. They remain usable until the printed expiration date as long as they have not exceeded the 28-day cumulative room-temperature limit or been frozen.
How heat affects Wegovy
Wegovy's heat sensitivity follows the same pattern as other semaglutide and tirzepatide products. The peptide structure depends on its three-dimensional shape, and heat accelerates the chemical reactions that disrupt this shape.
The 86-degree Fahrenheit ceiling is the temperature above which Novo Nordisk's stability data does not support the labeled 28-day window. Brief excursions slightly above 86 degrees do not cause immediate failure but accumulate risk. Sustained or extreme exposure should trigger discard.
Common heat exposures that exceed the ceiling:
- Cars in summer: interiors reach 110 to 140 degrees Fahrenheit within an hour
- Direct sunlight on packaging or bags
- Hot beach environments without insulation
- Bathrooms or rooms with heating sources near the medication
- Shipping in summer with cold-chain failures
Common locations within the 86-degree ceiling:
- Air-conditioned homes and offices
- Insulated travel pouches indoors
- Aircraft cabins
- Hotel rooms
- Refrigerators (well within range)
The practical guidance: keep Wegovy refrigerated when possible. Use the 28-day room-temperature window deliberately rather than by default. Avoid the 86-degree ceiling exposures listed above.
Freezing and the do-not-use rule
Novo Nordisk's labeling treats freezing as an absolute discard condition. A pen that has been frozen, even briefly, should be discarded even if it appears normal after thawing.
The reasons:
- Ice crystals can damage peptide structure
- The preservative can precipitate, affecting concentration uniformity
- Rubber components of the pen can crack or distort
- The cartridge seal can be compromised, allowing contamination
Visual inspection cannot reliably distinguish frozen-and-thawed Wegovy from undamaged medication. Some of the damage is microscopic or chemical and does not produce obvious appearance changes.
Locations where Wegovy may freeze:
- Back wall of home refrigerators during compressor cycles
- Top shelf below the freezer in top-freezer fridges
- Hotel mini-fridges that run too cold
- Refrigerator freezer compartments accessed by mistake
- Winter shipping in inadequately insulated packages
- Outdoor storage in cold climates
If you suspect freezing, the conservative answer is replacement. Pharmacies will typically replace pens damaged by storage failures, particularly those during shipping or pharmacy handling.
Stockpile management across dose changes
The Wegovy dose ladder creates a recurring stockpile question: what to do with pens at the current strength when a dose change is scheduled.
Practical guidance:
- Time refills to coincide with dose changes when possible
- Do not stockpile pens at multiple strengths simultaneously unless needed for specific clinical reasons
- Discard pens at obsolete strengths once you have moved up the ladder
- If pausing therapy, refrigerate current pens and resume at the same strength when restarting, with prescriber approval
For patients with insurance challenges or supply issues, sometimes a temporary stockpile makes sense. The 28-day room-temperature window provides some flexibility, but the cleaner approach is continuous refrigeration of stockpiled pens, with use within their printed expiration dates.
For patients on long-term maintenance dose (2.4 mg), the dose-change question recedes. Pens at the maintenance strength are received and used in roughly one-month cycles, with negligible stockpile concerns.
What changes for compounded semaglutide at weight-loss doses
Compounded semaglutide for weight loss is not Wegovy. The 28-day room-temperature rule does not apply.
Compounded semaglutide is prepared by 503A pharmacies. Doses approximate but do not exactly match the Wegovy ladder; many compounding pharmacies offer flexible dosing in custom increments. Pen or vial format varies by pharmacy.
Storage rules for compounded semaglutide:
- Set by the dispensing pharmacy on the medication label
- Typically based on USP 797 standards for compounded sterile preparations
- Beyond-use dates under refrigeration: usually 28 to 90 days
- Room-temperature allowances generally shorter than Wegovy's 28 days, often a few hours to a few days
Compounded semaglutide is not FDA-approved. It is legal under section 503A when prepared for an individual patient with a prescription. It does not have the stability data behind Wegovy or Ozempic and follows different storage rules accordingly.
Patients on compounded semaglutide should follow the storage instructions from their dispensing pharmacy. Do not assume Wegovy rules apply.
The contrary view: margin in the 28-day spec
The 28-day window is what Novo Nordisk validated for Wegovy. It is not the boundary at which semaglutide stops working.
Pharmaceutical stability testing typically demonstrates product specification well past the labeled window. The labels are calibrated to ensure margin between tested performance and commercial commitment. Wegovy on day 29 is almost certainly indistinguishable from Wegovy on day 28 in terms of clinical potency.
The argument for strict adherence: the label is the authoritative reference. Any individual interpretation of "close enough" creates inconsistent practice. The 28-day rule provides a clean, defensible line.
The argument for flexibility: a pen one day past the limit is unlikely to be clinically different from a pen at the limit. Discarding it creates waste without meaningful safety benefit. Patients paying out of pocket for Wegovy at retail prices have a real financial stake in marginal-overage decisions.
Most reasonable practice: follow the 28-day limit as default. Replace pens when uncertain. Accept marginal overages only when the alternative is meaningful disruption and the overage was small.
Decision framework for warm Wegovy pens
For a Wegovy pen that has been warmed or out of the fridge, walk through:
1. Has the pen exceeded 86 degrees Fahrenheit? If yes for more than a brief excursion, discard. If no, continue.
2. Has the pen been below 32 degrees Fahrenheit at any point? If yes, discard. If no, continue.
3. What is the cumulative time at room temperature? Under 28 days, usable. Over 28 days, discard.
4. Has the printed expiration date passed? If yes, discard. If no, continue.
5. Does the solution look clear and colorless through the pen window? If yes, use. If cloudy, discolored, or particulate, discard.
For ongoing patients, the cleanest habit is to refrigerate pens immediately on arrival and only warm each pen briefly before injection. This pattern uses essentially none of the 28-day window per pen and never approaches the cumulative limit.
FAQ
How long can Wegovy be out of the fridge?
Up to 28 days at room temperature below 86 degrees Fahrenheit.
Why is Wegovy's window shorter than Ozempic's even though both are semaglutide?
Different pen format, different formulation, different stability data submitted to FDA.
What temperature ruins Wegovy?
Above 86 degrees Fahrenheit or any freezing temperature.
How is Wegovy's pen different from Ozempic's?
Wegovy is single-dose; Ozempic is multi-dose. Wegovy has five dose strengths for titration.
Does Wegovy need to be refrigerated after taking the dose?
No, because each pen is single-dose and discarded after use.
Can I use Wegovy after it has been at room temperature for 4 weeks?
If under 28 days, yes. If at or past 28 days, discard.
How does the Wegovy dose ladder affect storage planning?
Pens at obsolete strengths may be discarded during titration. Time refills with dose changes when possible.
Does the 28-day rule apply to compounded semaglutide for weight loss?
No. Compounded products have shorter beyond-use dates set by the 503A pharmacy.
Related guides
- How Long Can Ozempic Be Out of the Fridge? The 56-Day Rule, Explained
- How Long Can Zepbound Be Out of the Fridge? The 21-Day Lilly Rule
- How Long Can Mounjaro Be Out of the Fridge? The 21-Day Rule for Type 2 Diabetes
- How Long Can Compounded Semaglutide Be Out of the Fridge? Beyond-Use Dating Explained
- How Long Does Wegovy Last in the Fridge? Pre-Use Shelf Life by Dose Step
- How to Travel With Wegovy: Dose-Ladder Travel and 28-Day Storage Tips
Sources
- Novo Nordisk Inc. Wegovy (semaglutide) injection prescribing information, revised 2024.
- U.S. Food and Drug Administration. Wegovy approval documentation, 2021.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA 2021;325(14):1414-1425.
- United States Pharmacopeia. USP General Chapter 797: Pharmaceutical Compounding Sterile Preparations, 2023 revision.
- International Conference on Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products, 2003.
- Manning MC, Patel K, Borchardt RT. Stability of Protein Pharmaceuticals. Pharmaceutical Research 2010;27(4):544-575.
- U.S. National Library of Medicine. DailyMed entry for Wegovy, accessed 2026.
- Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology 2019;10:155.
- American Society of Health-System Pharmacists. Drug stability and storage practical guidance, 2024.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT Trial). New England Journal of Medicine 2023;389:2221-2232.
Footer disclaimers
Platform Disclaimer. FormBlends offers telehealth services and educational content. This article does not substitute for personal medical advice. Storage instructions specific to your medication and your situation should come from your prescriber and pharmacy.
Compounded Medication Notice. Compounded semaglutide is not FDA-approved and follows different storage rules from Wegovy. Beyond-use dates for compounded preparations are set by the 503A pharmacy that prepared them, following USP 797 standards.
Results Disclaimer. Storage outside the labeled range can reduce medication potency, which may affect appetite control, weight outcomes, and other treatment effects. Specific clinical consequences of individual storage incidents are difficult to predict.
Trademark Notice. Wegovy is a registered trademark of Novo Nordisk A/S. Ozempic is a registered trademark of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends has no commercial affiliation with these companies.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →